COVID Vaccine Trials May Need Active Comparators Once Adequate Supply Reached, CBER’s Marks Says
US FDA’s biologics center director Peter Marks discusses future COVID-19 vaccine trials, post-market safety monitoring, and how FDA is juggling reviewing two emergency use authorization requests at once in an interview with Pink Sheet.
